Translational Oncogenomic Unit, Italian National Cancer Institute Regina Elena, Rome, Italy.
Cell Death Dis. 2012 Nov 15;3(11):e423. doi: 10.1038/cddis.2012.160.
Micro RNAs (miRs) are small non-coding RNAs aberrantly expressed in human tumors. Here, we aim to identify miRs whose deregulated expression leads to the activation of oncogenic pathways in human gastric cancers (GCs). Thirty nine out of 123 tumoral and matched uninvolved peritumoral gastric specimens from three independent European subsets of patients were analyzed for the expression of 851 human miRs using Agilent Platform. The remaining 84 samples were used to validate miRs differentially expressed between tumoral and matched peritumoral specimens by qPCR. miR-204 falls into a group of eight miRs differentially expressed between tumoral and peritumoral samples. Downregulation of miR-204 has prognostic value and correlates with increased staining of Bcl-2 protein in tumoral specimens. Ectopic expression of miR-204 inhibited colony forming ability, migration and tumor engraftment of GC cells. miR-204 targeted Bcl-2 messenger RNA and increased responsiveness of GC cells to 5-fluorouracil and oxaliplatin treatment. Ectopic expression of Bcl-2 protein counteracted miR-204 pro-apoptotic activity in response to 5-fluorouracil. Altogether, these findings suggest that modulation of aberrant expression of miR-204, which in turn releases oncogenic Bcl-2 protein activity might hold promise for preventive and therapeutic strategies of GC.
微小 RNA(miRs)是在人类肿瘤中异常表达的小非编码 RNA。在这里,我们旨在确定那些表达失调导致人类胃癌(GC)中致癌途径激活的 miRs。使用 Agilent 平台分析了来自三个独立的欧洲患者亚组的 39 个肿瘤和匹配的非肿瘤旁胃标本中的 123 个 tumoral 和匹配的 uninvolved peritumoral 胃标本中的 851 个人类 miRs 的表达。其余 84 个样本用于通过 qPCR 验证肿瘤和匹配的 tumoral 样本之间差异表达的 miRs。miR-204 属于一组在肿瘤和 peritumoral 样本之间差异表达的 8 个 miRs 之一。miR-204 的下调具有预后价值,并与肿瘤标本中 Bcl-2 蛋白的增加染色相关。miR-204 的异位表达抑制了 GC 细胞的集落形成能力、迁移和肿瘤植入。miR-204 靶向 Bcl-2 信使 RNA,并增加了 GC 细胞对 5-氟尿嘧啶和奥沙利铂治疗的反应性。异位表达 Bcl-2 蛋白可拮抗 miR-204 对 5-氟尿嘧啶的促凋亡活性。总之,这些发现表明,调节异常表达的 miR-204,从而释放致癌的 Bcl-2 蛋白活性,可能为 GC 的预防和治疗策略提供希望。